扶正化瘀胶囊联合恩替卡韦对乙型肝炎肝硬化患者肝纤维化及肝功能指标的影响  

Effect of Fuzheng Huayu Capsule combined with entecavir on liver fibrosis and liver function indexes in patients with hepatitis B virus-related liver cirrhosis

作　　者：苏园园 黄诚山 王海[1] SU Yuanyuan;HUANG Chengshan;WANG Hai Lianjiang(People’s Hospital,Guangdong,Liangjiang 524400,China)

机构地区：[1]广东省廉江市人民医院,广东廉江524400

出　　处：《中国医药科学》2022年第7期106-109,共4页China Medicine And Pharmacy

摘　　要：目的探讨扶正化瘀胶囊联合恩替卡韦在乙型肝炎肝硬化(HBLC)患者中的治疗效果。方法选取2019年10月至2020年10月廉江市人民医院收治的98例HBLC患者,按随机数字表法分成对照组49例、观察组49例。对照组使用恩替卡韦,观察组加用扶正化瘀胶囊,连续用药24周。比较两组临床疗效、肝纤维化指标、肝功能指标及不良反应。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗前,两组透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、总胆红素(TBIL)、谷草转氨酶(AST)、谷丙转氨酶(GPT)水平比较,差异无统计学意义(P>0.05);治疗后,观察组HA、LN、PCⅢ、TBIL、AST、GPT水平低于对照组,差异有统计学意义(P<0.05);两组不良反应相当,差异无统计学意义(P>0.05)。结论扶正化瘀胶囊联合恩替卡韦在HBLC患者治疗中效果确切,能够明显抑制肝纤维化,改善肝功能,且不会增加不良反应,安全可行。Objective To investigate therapeutic effects of Fuzheng Huayu Capsule combined with entecavir in patients with hepatitis B virus-related liver cirrhosis(HBLC).Methods A total of 98 HBLC patients treated in Lianjiang People’s Hospital from October 2019 to October 2020 were selected and divided into the control group(n=49)and the observation group(n=49)by the random number table method.The control group was treated with entecavir and the observation group was additionally administered Fuzheng Huayu Capsules for consecutive 24 weeks.The clinical efficacy,liver fibrosis indexes,liver function indexes and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,with statistically significant difference(P<0.05).Before treatment,there were no statistically significant differences in the levels of hyaluronic acid(HA),laminin(LN),typeⅢprocollagen(PCⅢ),total bilirubin(TBIL),aspartate aminotransferase(AST)and glutamic-pyruvic transaminase(GPT)between the two groups(P>0.05).After treatment,the levels of HA,LN,PCⅢ,TBIL,AST and GPT in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion Fuzheng Huayu Capsule combined with entecavir is effective in the treatment of HBLC patients and can significantly inhibit liver fibrosis and improve liver function without increasing adverse reactions.It is safe and feasible.

关 键 词：乙型肝炎肝硬化 扶正化瘀胶囊 恩替卡韦 肝纤维化 肝功能 

分 类 号：R512.62[医药卫生—内科学]